• Advertise
  • Donate
  • Subscribe
    • Become a print subscriber
    • Sign up for e-Newsletter
    • e-Editions
Tuesday, September 26, 2023
No Result
View All Result
Minnesota Spokesman-Recorder
  • News & Features
    • National
    • Local
    • Special Editions
      • MLK Legacy
      • Black History Month
      • The MSR Celebrates Women’s History Month
  • All Sections
    • Opinion
      • Mellaneous by Mel Reeves
      • Word on the Street
      • Reaching Out From Within
    • Health + Wellness
      • Women’s Wellness
      • Parenting Today
      • Minnesota Cancer Alliance Breast Cancer Gaps Project
    • Sports
      • Timberwolves/NBA
      • Lynx/WNBA
        • 20 in 20
      • Twins/MLB
      • MN Wild/NHL
      • Vikings/NFL
    • Business
      • Small Business Month Celebration
      • Black Business Spotlight
      • Finances FYI
    • Arts + Culture
    • Photo Galleries
      • Photo of the Week
    • MSR Forefront Digital Roundtable Series
      • MSR Forefront Highlights
    • Go Green
    • Education
    • Bulletin
    • Jobs & Notices
      • Legals
      • Announcements
  • Events
    • Submit an event!
  • Obits
  • Sister Spokesman
  • e-Editions
Minnesota Spokesman-Recorder
  • News & Features
    • National
    • Local
    • Special Editions
      • MLK Legacy
      • Black History Month
      • The MSR Celebrates Women’s History Month
  • All Sections
    • Opinion
      • Mellaneous by Mel Reeves
      • Word on the Street
      • Reaching Out From Within
    • Health + Wellness
      • Women’s Wellness
      • Parenting Today
      • Minnesota Cancer Alliance Breast Cancer Gaps Project
    • Sports
      • Timberwolves/NBA
      • Lynx/WNBA
        • 20 in 20
      • Twins/MLB
      • MN Wild/NHL
      • Vikings/NFL
    • Business
      • Small Business Month Celebration
      • Black Business Spotlight
      • Finances FYI
    • Arts + Culture
    • Photo Galleries
      • Photo of the Week
    • MSR Forefront Digital Roundtable Series
      • MSR Forefront Highlights
    • Go Green
    • Education
    • Bulletin
    • Jobs & Notices
      • Legals
      • Announcements
  • Events
    • Submit an event!
  • Obits
  • Sister Spokesman
  • e-Editions
No Result
View All Result
Minnesota Spokesman-Recorder
No Result
View All Result

Newly approved drug a trail-blazing approach to cancer treatment

by Charles Crutchfield III MD
December 13, 2018
11
SHARES
224
VIEWS
Share on FacebookShare on LinkedIn
Courtesy of Dr. Crutchfield

The FDA just approved a new revolutionary drug for the treatment of cancer. The medication, Vitrakvi (larotrectinib), is unique in that it treats the geneticbasis of what is driving cancer and not the type of cancer once it hasdeveloped.

The mutation that causes cells to become cancerous is found in many different types of cancers. So, this new treatment is not just for one cancer but may treat many different types of cancer. This is avant-garde thinking.

Vitrakvi (larotrectinib) is manufactured by Bayer and is available in pill and liquid forms. It can treat cancers in children and adults, but it isn’t cheap. For adults, the medicine is just under $400,000 per year. In children, the cost is about $135,000 per year.

How does Vitrakvi (larotrectinib) work?

This drug works by blocking a specific mutated enzyme (tyrosine kinase) in cancer cells. When present, this defective enzyme causes cancerous growth in many different types of cancer.

- ADVERTISEMENT -

Why is it revolutionary?

Vitrakvi (larotrectinib)is one of the first drugs of its kind that focuses on treating the genetic basis of cancer, not just the type of cancer. That is, it goes after the switch that turns a normal cell into a cancerous cell.

By analogy, there are many types of car manufacturers. Instead of trying to treat a single entity, like a Chevy or a Ford or Honda, this medicine focuses on treating the force that makes the cars go — the engine!

As a result, this radical approach has the potential of treating many kinds of cancers (all cars have engines) rather than a specific type of cancer (Chevy, Ford or Honda). This groundbreaking approach has a much broader potential in the war against cancer. By developing the ability to stop the engine of any car, there is the potential of stopping many different types of cars from running, which supports the analogy of fighting many kinds of cancer.

Since it is FDA-approved, will insurance cover it?

- ADVERTISEMENT -

Yes and no. The drug has a broad appeal and the benefit of treating both children and adults.  Unfortunately, the price tag is astronomical.

Medicare and Medicaid are not covering the medication yet, but it is hopeful that they will.  If they do, third-party payers usually follow suit, but once again, due to cost, any and all insurances may have restrictions, limitations, and only partial coverage. Insurance coverage, of course, will improve as the price comes down.

If someone has cancer, how do they discover if this medicine will work for them?

The appeal of this medication is that it works in many different cancers both in children and adults. This fact, by itself, is remarkable and substantial.

Unfortunately, the type of genetic mutation that drives these cancers represents only a small percentage of overall cancers, probably less than five percent. So, it certainly won’t work in all cancers. But when it does work — and it has already helped many patients in the tests and trials — some patients have experienced remarkable results.

- ADVERTISEMENT -

We currently don’t know which cancers will respond. Fortunately, tests will be available to see if a person’s cancer is responsive to this new treatment. A person’s cancer will be mapped for mutations. Once the mutations are discovered, any available medications that attack that mutation can be employed.

Hopefully, over time, we will build a bigger and bigger army of medicines that attack a wide variety of genetic mutations that cause a wide range of cancers located anywhere in the body. Unfortunately, these tests are new, expensive and challenging. They will very likely get better and less costly on a rapid and regular basis. Regardless, people should get tested, because we now have a revolutionary and effective treatment for select cancer patients.

The future of cancer treatment

Vitrakvi (larotrectinib) is the first medication designed specifically to attack cancers based on the gene mutations that make them malignant and not where they occur in the body or the type of tissue the cancer comes from. We will no longer treat the tissue where cancer comes from; we will address the DNA mutation that causes a cancer in the first place.

Calling a cancer by the mutation that causes it and not the tissue or organ it comes from, such as breast or prostate cancer, is a trail-blazing approach in the treatment of cancer. It now shifts our thinking and focus when it comes to treating and curing cancer. This new view is the future of cancer treatment.

- ADVERTISEMENT -

We no longer need to consider or call cancer the name based on its tissue type. We will now look at cancers based on the gene mutations that drive them. These very mutations can then be detected, and drugs can be designed and selected to attack the mutations.

Attacking the genetic cause of malignancy has been the Holy Grail for cancer treatment, and we are now about to sip from the cup. The future has never been brighter for the war on cancer.

Related content: 

New advances in the war on cancer: living cell therapy

What is cancer?

Good news: we are winning the war on cancer

Support Black local news

Help amplify Black voices by donating to the MSR. Your contribution enables critical coverage of issues affecting the community and empowers authentic storytelling.

Donate Now!

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to print (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

Like this:

Like Loading...
ADVERTISEMENT
Previous Post

Let’s talk Whiteness: ‘Minnesota Nice’ and prejudice explored at race forum

Next Post

Who says women can’t be NFL head coaches?

Charles Crutchfield III MD

Charles E. Crutchfield III, MD was the senior medical advisor for the Minnesota Spokesman-Recorder until his passing on June 21, 2023. He launched and helped organize a weekly Doctor's Advice column where he and other Black physicians offered timely medical advice on pertinent topics in the Black community. Dr. Crutchfield III was a board-certified dermatologist and clinical professor of dermatology at the University of Minnesota Medical School and a Benedict Distinguished Visiting Professor of biology at Carleton College. He also had a private practice, Crutchfield Dermatology in Eagan, MN. He received his MD and master’s degree in molecular biology and genomics from the Mayo Clinic. He had been selected as one of the top 10 dermatologists in the United States by Black Enterprise magazine. Minnesota Medicine recognized Dr. Crutchfield as one of the 100 Most Influential Healthcare Leaders in Minnesota. Dr. Crutchfield specialized in skincare for people of color and has been selected by physicians and nurses as one of the leading dermatologists in Minnesota for the past 18 years. He was the team dermatologist for the Minnesota Twins, Vikings, Timberwolves, Wild and Lynx. Dr. Crutchfield was an active member of both the American and National Medical Associations and president of the Minnesota Association of Black Physicians.

You Might Also Like

No Content Available
Next Post
NFL

Who says women can’t be NFL head coaches?

  • Facebook
  • Instagram
  • Twitter
  • YouTube
ADVERTISEMENT

Upcoming Events

Sep 12
September 12 @ 6:30 pm-December 18 @ 9:30 pm Recurring

Vic Volare Presents MUSIC FOR MARTINIS ft: Vic’s Fabulous Nightclub Academy

Sep 26
7:00 pm-9:00 pm

Climate and Equity in Minneapolis: What we could win in this year’s budget

Sep 27
8:00 am-12:45 pm

It’s Time to Talk: Forums on Race™

Sep 27
7:30 pm-9:30 pm Recurring

Ayodele Casel Rooted

View Calendar
ADVERTISEMENT
ADVERTISEMENT

Read our latest e-Edition!

ADVERTISEMENT
ADVERTISEMENT

Subscribe

  • Home/Office Delivery
  • Weekly e-newsletter
  • e-Editions

Support

  • Donate
  • Subscribe
  • MSR Newsstand Locations

Connect

  • About
    • MSR Staff
  • Contact
  • Send a news tip
  • About
  • Privacy Policy
  • Terms

© 2023 Minnesota Spokesman-Recorder

No Result
View All Result
  • News & Features
    • Local
    • National
  • All Sections
    • Arts & Culture
    • Health & Wellness
      • Women’s Wellness
      • Parenting Today
      • MN Cancer Alliance Breast Cancer Gaps Project
    • Business
      • Black Business Spotlight
      • Finances FYI
      • Small Business Month Celebration
    • Opinion
    • Sports
  • Events
  • Obits
  • Sister Spokesman
  • Donate
  • Subscribe

© 2023 Minnesota Spokesman-Recorder

 

Loading Comments...
 

    %d bloggers like this: